Search results
Our iconic brands have a new home where thoughtful everyday care meets scientific precision. As a global consumer health leader, Kenvue touches the lives of more than a billion people across the globe.
Sep 28, 2022 · Kenvue Post-Separation: A Leading Global Consumer Health Company with Iconic Brands and Commitment to Continued Innovation. Kenvue will become a standalone leading global consumer health company in 2023, subject to legal requirements including consultation with works councils and employee representatives, as required.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue is the proprietor of well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Mylanta, Neutrogena, Trosyd, Tylenol, and Visine.
Aug 23, 2023 · SKILLMAN, N.J. August 23, 2023 – Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced its separation from Johnson & Johnson, marking its first day as a fully independent company.
Jul 31, 2023 · If you’ve heard of Kenvue, you may already know that we’re a global consumer health company. But beyond our portfolio of iconic brands, Kenvue is built on a foundation of core values, which fuel our 22,000+ global team members every day. Here’s what you need to know: 1. You already know us
Sep 28, 2022 · Kenvue Post-Separation: A Leading Global Consumer Health Company with Iconic Brands and Commitment to Continued Innovation
May 3, 2023 · J&J's consumer health spinoff, Kenvue, is expected to set an initial public offering price Wednesday night and trade Thursday on the New York Stock Exchange.
当社の象徴的なブランドは、思慮深い日常のケアとサイエンスの精度を融合した新しい拠点を築きました。Kenvueはグローバルコンシューマーヘルスリーダとして、世界中の10億人以上の人々の生活に関わっています。
Find the latest Kenvue Inc. (KVUE) stock quote, history, news and other vital information to help you with your stock trading and investing.
May 4, 2023 · Johnson & Johnson’s consumer-health spinoff Kenvue started trading on the New York Stock Exchange under the stock ticker KVUE. Thursday’s move values the new company at roughly $50 billion ...
